<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463525</url>
  </required_header>
  <id_info>
    <org_study_id>D5160C00043</org_study_id>
    <nct_id>NCT03463525</nct_id>
  </id_info>
  <brief_title>Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases</brief_title>
  <acronym>ODIN-BM</acronym>
  <official_title>An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single centre, Phase I study to determine the brain exposure of&#xD;
      [11C]osimertinib in patients with EGFRm NSCLC with brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-centre, Open-label, PET imaging and Pharmacokinetic Study of IV Administered&#xD;
      [11C]osimertinib in EGFRm Non-small cell lung cancer patients with brain metastases. The&#xD;
      study will consist of 2 phases, an imaging phase and a continuous access phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Exposure to [11C]osimertinib in Tumour Region of Interest</measure>
    <time_frame>PET Scan on Day 1</time_frame>
    <description>Measurement of the brain standard uptake value (SUV) seen on PET scan at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib</measure>
    <time_frame>Blood samples collected on Day 1 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Brain to Plasma Ratio of Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Measurement collected on Day 1 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Measurement of the brain to plasma partition coefficient (concentration brain/plasma ratio) by assessment of area under the concentration-time curve, derived from the curve taken at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Radioactivity by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 1 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib radioactivity by assessment of time to Cmax (Tmax), derived from the curve taken at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Exposure to [11C]osimertinib in Tumour Region of Interest</measure>
    <time_frame>PET Scan on Day 2</time_frame>
    <description>Measurement of the brain standard uptake value (SUV) seen on PET scan after a single dose of oral osimertinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Exposure to [11C]osimertinib in Tumour Region of Interest</measure>
    <time_frame>PET Scan on Day 29</time_frame>
    <description>Measurement of the brain standard uptake value (SUV) seen on PET scan after at least 21days of continuous oral osimertinib dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib</measure>
    <time_frame>Blood samples collected on Day 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib</measure>
    <time_frame>Blood samples collected on Day 29 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Radioactivity by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 2 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib radioactivity by assessment of time to Cmax (Tmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Radioactivity by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 29 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib radioactivity by assessment of time to Cmax (Tmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Brain to Plasma Ratio of Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Measurement collected on Day 2 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Measurement of the brain to plasma partition coefficient (concentration brain/plasma ratio) by assessment of area under the concentration-time curve, derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Brain to Plasma Ratio of Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Measurement collected on Day 29 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Measurement of the brain to plasma partition coefficient (concentration brain/plasma ratio) by assessment of area under the concentration-time curve, derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib and its Metabolite by Assessment of AUC Metabolite to Parent Ratio</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 2, 4 and 7.5 hour(s) post dose (can be modified if necessary).</time_frame>
    <description>Pharmacokinetics of osimertinib and its metabolite by assessment of AUC metabolite to parent ratio, derived from the curves taken during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 2, 4 and 7.5 hour(s) post dose (can be modified if necessary).</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Area Under the Concentration-time Curve</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 2, 4 and 7.5 hour(s) post dose (can be modified if necessary).</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of area under the concentration-time curve from time zero to the last measurable time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 2, 4 and 7.5 hour(s) post dose (can be modified if necessary).</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of time to Cmax (Tmax), derived from the curve taken during the treatment period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] with IV [11C]osimertinib administration</measure>
    <time_frame>From study Day 1 and until 30 days after the study drug is discontinued.</time_frame>
    <description>Collection and assessment of adverse events graded using CTCAE (version 4.03).</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] with continuous oral osimertinib</measure>
    <time_frame>From study Day 1 and until 30 days after the study drug is discontinued.</time_frame>
    <description>Collection and assessment of adverse events using CTCAE (version 4.03)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>[11C]osimertinib + oral osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.</description>
    <arm_group_label>[11C]osimertinib + oral osimertinib</arm_group_label>
    <other_name>Tagrisso</other_name>
    <other_name>AZD9291</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]osimertinib</intervention_name>
    <description>Patients will receive 3 single IV microdose administrations of [11C]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.</description>
    <arm_group_label>[11C]osimertinib + oral osimertinib</arm_group_label>
    <other_name>[11C]AZD9291</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures, sampling and analyses. Procedures performed for routine clinical practice&#xD;
             up to 2 weeks before the provision of written consent are acceptable if not&#xD;
             intentionally done for study purposes.&#xD;
&#xD;
             If a patient declines to participate in any voluntary exploratory research and/or&#xD;
             genetic component of the study, there will be no penalty or loss of benefit to the&#xD;
             patient and he/she will not be excluded from other aspects of the study.&#xD;
&#xD;
          2. Male or female aged at least 18 years.&#xD;
&#xD;
          3. Histological or cytological confirmation of diagnosis of NSCLC.&#xD;
&#xD;
          4. Confirmation that the tumour harbours an EGFR mutation known to be associated with&#xD;
             EGFR-TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) or T790M EGFR&#xD;
             resistance mutation as assessed by local laboratory/or central laboratory via&#xD;
             tissue/cytology or in plasma.&#xD;
&#xD;
          5. Mandatory provision (if available) of formalin fixed, paraffin embedded tissue and&#xD;
             blood for central confirmation of EGFR mutation status. Please refer to the Laboratory&#xD;
             Manual for details.&#xD;
&#xD;
          6. In all patients enrolled, confirmed BM as having at least one non-measurable and/or&#xD;
             measurable brain lesion at baseline as per CNS RECIST 1.1 via MRI imaging.&#xD;
&#xD;
          7. World Health Organisation (WHO) performance status 0 to 2 and a minimum life&#xD;
             expectancy of 4 weeks.&#xD;
&#xD;
          8. Females should be using adequate contraceptive measures (up to 6 months after the last&#xD;
             administration), should not be breastfeeding and must have a negative serum pregnancy&#xD;
             test prior to start of dosing if of childbearing potential or must have evidence of&#xD;
             non-childbearing potential by fulfilling 1 of the following criteria at screening:&#xD;
&#xD;
               -  Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least&#xD;
                  12 months following cessation of all exogenous hormonal treatments.&#xD;
&#xD;
               -  Women under 50 years old would be consider postmenopausal if they have been&#xD;
                  amenorrhoeic for 12 months or more following cessation of exogenous hormonal&#xD;
                  treatments and with luteinising hormone (LH) and follicle-stimulating hormone&#xD;
                  (FSH) levels in the post-menopausal range for the institution.&#xD;
&#xD;
               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral&#xD;
                  oophorectomy or bilateral salpingectomy but not tubal ligation.&#xD;
&#xD;
          9. Male subjects should be willing to use barrier contraception&#xD;
&#xD;
         10. Have a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 inclusive and weigh at&#xD;
             least 40.0 kg and no more than 100.0 kg, inclusive&#xD;
&#xD;
         11. Able and willing to participate in all scheduled evaluations, abide by all study&#xD;
             restrictions, and complete all required tests and procedures.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Participation in another clinical study with an IP during the previous 14 days (or&#xD;
             longer, depending on characteristics of agents used).&#xD;
&#xD;
          2. Treatment with any of the following: EGFR-TKI (e.g. erlotinib, gefitinib or afatinib)&#xD;
             within 10 days or at least 5x the half-life, whichever is the longer; any cytotoxic&#xD;
             chemotherapy, investigational agents or other anticancer drugs within 14 days of start&#xD;
             of IP; osimertinib in the present or other studies; major surgery (excluding placement&#xD;
             of vascular access) within 4 weeks of start of IP; radiotherapy (including brain) with&#xD;
             a limited field of radiation within 1 week of start of IP, except in patients&#xD;
             receiving radiation to more than 30% of the bone marrow or with a wide field of&#xD;
             radiation which must be completed within 4 weeks of the first administration of the&#xD;
             IP; current receipt (or inability to stop at least 3 weeks before study start)&#xD;
             medications or herbal supplements known to be potent inducers of CYP3A4.&#xD;
&#xD;
          3. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of&#xD;
             starting the IP with the exception of alopecia and grade 2, prior platinum&#xD;
             therapy-related neuropathy.&#xD;
&#xD;
          4. History of brain surgery or major brain trauma in the last year (if the surgery is in&#xD;
             the same hemisphere as the brain metastasis).&#xD;
&#xD;
          5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension and active bleeding diatheses or active infection including hepatitis B,&#xD;
             hepatitis C and HIV.&#xD;
&#xD;
          6. Any of the following cardiac criteria:&#xD;
&#xD;
               -  Mean resting corrected QT interval (QTc) &gt;470 msec obtained from 3 ECGs, using&#xD;
                  the screening clinic ECG machine derived QTc value.&#xD;
&#xD;
               -  Any clinically important abnormalities in rhythm, conduction or morphology of&#xD;
                  resting ECG (eg, complete left bundle branch block, third degree heart block,&#xD;
                  second degree heart block).&#xD;
&#xD;
               -  Patient with any factors that increase the risk of QTc prolongation or risk of&#xD;
                  arrhythmic events such as electrolyte abnormalities including:&#xD;
&#xD;
                    -  Serum/plasma potassium &lt;lower limit of normal (LLN)&#xD;
&#xD;
                    -  Serum/plasma magnesium &lt;lower limit normal (LLN)&#xD;
&#xD;
                    -  Serum/plasma calcium &lt;lower limit normal (LLN)&#xD;
&#xD;
               -  Heart failure, congenital long QT syndrome, family history of long QT syndrome,&#xD;
                  or unexplained sudden death under 40 years of age in first-degree relatives or&#xD;
                  any concomitant medication known to prolong the QT interval and cause Torsades de&#xD;
                  Pointes.&#xD;
&#xD;
          7. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required&#xD;
             steroid treatment, or any evidence of clinically active ILD.&#xD;
&#xD;
          8. Inadequate bone marrow reserve or organ function as demonstrated by any of the&#xD;
             following laboratory values:&#xD;
&#xD;
               -  ANC &lt;1.5 × 109/L; Platelets &lt;100 × 109/L; Haemoglobin &lt;90 g/L;&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt;2.5x ULN or &gt;5x ULN in the presence of liver&#xD;
                  metastases;&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt;2.5x ULN or &gt;5x ULN in the presence of liver&#xD;
                  metastases;&#xD;
&#xD;
               -  Total bilirubin &gt;1.5x ULN or &gt;3x ULN in the presence of liver metastases or&#xD;
                  Gilbert's Syndrome;&#xD;
&#xD;
               -  Creatinine &gt;1.5xl ULN concurrent with creatinine clearance &lt;50 mL/min (using&#xD;
                  Cockcroft-Gault formula).&#xD;
&#xD;
          9. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to&#xD;
             swallow the tablet or previous significant bowel resection that would preclude&#xD;
             adequate absorption of osimertinib.&#xD;
&#xD;
         10. History of hypersensitivity to active or inactive excipients of osimertinib or drugs&#xD;
             with a similar chemical structure or class to osimertinib.&#xD;
&#xD;
         11. In addition, the following is considered a criterion for exclusion from the&#xD;
             exploratory genetic research:&#xD;
&#xD;
               -  Previous allogenic bone marrow transplant&#xD;
&#xD;
               -  Non-leukocyte depleted whole blood transfusion within 120 days of the date of the&#xD;
                  genetic sample collection&#xD;
&#xD;
         12. Patients on anticoagulant treatment.&#xD;
&#xD;
         13. Absence of collateral flow between ulnar and radial artery as assessed by the Allen´s&#xD;
             test&quot;.&#xD;
&#xD;
         14. Suffering from claustrophobia and/or having implanted metal devices or implants such&#xD;
             as pacemaker, vascular or heart valves or metal deposits such as bullets, shells,&#xD;
             metal grains in the eyes.&#xD;
&#xD;
         15. Previous participation in a research PET or PET/CT study.&#xD;
&#xD;
         16. The following are exclusion criteria for contrast enhanced MRIs:&#xD;
&#xD;
               -  Glomerular filtration rate &lt;30 ml/min&#xD;
&#xD;
               -  History of renal insufficiency&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
         17. Women who are breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Ekman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE 11 282</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

